Preventing excessive bleeding in hemophilia patients during major surgery

A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures

This study is testing a new treatment to see if it can help prevent excessive bleeding during major surgeries for male adolescents and adults with hemophilia who have certain complications.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 19 (estimated)
• Ages: 12 Years to 65 Years
• Sex: Male
• Sponsor: Laboratoire français de Fractionnement et de Biotechnologies (Industry-sponsored)
• Drugs / interventions: emicizumab
• Locations: 14 sites (Los Angeles, California and 13 other locations)
• Trial ID: NCT05695391 on ClinicalTrials.gov

What this trial studies

This Phase 3 interventional study evaluates the safety and efficacy of Coagulation Factor VIIa (Recombinant) in preventing excessive bleeding in male adolescents and adults with congenital hemophilia A or B who have inhibitors to factor VIII or IX. The study is designed as a prospective, international, multicenter, single-arm trial, focusing on patients undergoing elective major surgical procedures. Participants will be monitored for bleeding events and safety outcomes following treatment with the intervention.

Who should consider this trial

Good fit: Ideal candidates are male patients diagnosed with congenital hemophilia A or B who have inhibitors to factor VIII or IX.

Not a fit: Patients without congenital hemophilia or those who do not have inhibitors to factor VIII or IX may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce the risk of excessive bleeding during major surgeries for hemophilia patients.

How similar studies have performed: Previous studies have shown promising results with similar interventions in managing bleeding in hemophilia patients, suggesting potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

Each patient must meet the following criteria to be enrolled in this study:

1. be male with a diagnosis of congenital hemophilia A or B of any severity
2. have one of the following:

   1. positive inhibitor test BU ≥5 (as confirmed at screening by the institutional lab) OR
   2. an inhibitor test BU \<5 (as confirmed at screening by the institutional lab) but expected to have an anamnestic response to FVIII or FIX, as demonstrated by a history of a high-responding inhibitor manifested by a previous anamnestic response, defined as a peak inhibitor titer \>5 BU after re-exposure to factor concentrates, precluding the use of FVIII or FIX products to treat or prevent bleeding OR
   3. an inhibitor test BU \<5 (as confirmed at screening by the institutional lab) but expected to be refractory to FVIII or FIX, as demonstrated by the patient's history of previous failure to respond to FVIII or FIX concentrates, even in the absence of a documented anamnestic response, precluding the use of FVIII or FIX products to treat or prevent bleeding episodes.
3. be ≥12 years to ≤65 years of age on the day of informed consent
4. be scheduled for an elective major surgical procedure as defined in the study protocol (see Table ''Definitions for the specific purpose of Study F7TG2202'')
5. have Hb ≥ 12 g/dL
6. be capable of understanding and willing to comply with the conditions of the protocol OR in the case of a patient under the age of legal majority, parent(s)/legal guardian(s) must be capable of understanding and willing to comply with the conditions of the protocol
7. have read, understood, and provided written informed consent (patient or parent(s)/legal guardian(s) if the patient is minor according to local regulation) and, where applicable according to local regulation, patient's assent if the patient is minor -

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study.

1. have any coagulation disorder other than hemophilia A or B
2. be immunosuppressed (i.e. the patient should not be receiving systemic immunosuppressive medication; CD4+ cell counts at screening should be \>200/μL)
3. known intolerance to LR769 or any of its excipients
4. currently receiving immune tolerance induction (ITI) therapy
5. have a known or suspected allergy or hypersensitivity to rabbits or rabbit proteins
6. have platelet count \<100,000/μL
7. have received an investigational drug within 30 days or within 5 half-lives of that investigational drug, whichever is longer, of the planned first LR769 administration, or be expected to receive such drug during participation in this study. Patients who have received fitusiran in a clinical study may not participate in this clinical study for 6 months since the last dose and if they have an antithrombin III level not in the normal range at screening.
8. for patients using emicizumab, have received during the last 6 months or currently receiving a maintenance dosing regimen of emicizumab different from the indicated one ± 10% of approved dose), i.e. different from 1.5 mg/kg once weekly (±10%), 3 mg/kg (±10%) every two weeks or 6 mg/kg (±10%) every four weeks
9. for patients using emicizumab, currently be any plans, or notes in the patient's medical records that would suggest the need to increase or decrease emicizumab dosing due to antidrug antibodies (ADAs), reduced PK, or coagulation/safety-related issues (e.g. lack of response, or potential/actual thromboembolic concerns, etc)
10. have a clinically relevant hepatic (aspartate aminotransferase \[AST\] and/or alanine aminotransferase \[ALT\] \>3 times the upper limit of normal \[ULN\]) and/or renal impairment (creatinine \>2 times the ULN)
11. have a history of arterial and/or venous thromboembolic events (such as myocardial infarction, ischemic strokes, transient ischemic attacks, DVT, or PE) within 2 years prior to the planned first dose of LR769, uncontrolled arrhythmia, or current New York Heart Association (NYHA) functional classification score of stages II - IV
12. have an active malignancy (those with non-melanoma skin cancer are allowed)
13. have any life-threatening disease or other disease or condition which, according to the investigator's judgment, could imply a potential hazard to the patient, or interfere with the study participation or study outcome (e.g. chronic, unmanaged hepatitis infection)
14. be using aspirin, non-steroidal anti-inflammatory drugs (NSAIDS), herbs, natural medications, or other drugs with platelet inhibitory properties within one week prior to surgery and for the duration of treatment with LR769
15. have active gastric or duodenal ulcer disease
16. have received a FVII- or FVIIa-containing product (either plasma derived or recombinant) within 24 hours prior to administration of LR769
17. have a contraindication to antifibrinolytics
18. have planned combined major surgeries at the same time
19. be administered pharmacologic thromboprophylaxis within 5 half-lives of that medication before surgery or for the duration of treatment with LR769 -

Where this trial is running

Los Angeles, California and 13 other locations

• Orthopaedic Institute for Children - Orthopaedic Hemophilia Treatment Center — Los Angeles, California, United States (Not_yet_recruiting)
• Children's Healthcare of Atlanta — Atlanta, Georgia, United States (Recruiting)
• Tulane Univertsity School of Medecine — New Orleans, Louisiana, United States (Recruiting)
• M Health Fairview Center for bleeding and Clotting disorders — Minneapolis, Minnesota, United States (Recruiting)
• University of Texas Health Science Center at Houston — Houston, Texas, United States (Recruiting)
• Hospital Queen Elisabeth - Kota Kinabalu — Kota Kinabalu, Sabah Province, Malaysia (Recruiting)
• Hospital Ampang — Ampang, Selangor Province, Malaysia (Recruiting)
• Hospital Universitario Dr. José Eleuterio González de Nuevo León — Monterrey, Nuevo León, Mexico (Not_yet_recruiting)
• Charlotte Maxeke Johannesburg Academic Hospital — Johannesburg, Gauteng Province, South Africa (Recruiting)
• Chiang Mai University — Chiang Mai, Thailand (Recruiting)
• Maharaj Nakorn Chiangmai Hospital, Chiangmai University — Chiang Mai, Thailand (Recruiting)
• Acibadem Adana Hospital — Seyhan, Adana Province, Turkey (Recruiting)
• Hacettepe Üniversitesi Rektörlüğü Sihhiye — Altındağ, Ankara Province, Turkey (Not_yet_recruiting)
• Istanbul Üniversitesi Onkoloji Enstitusu — Fatih, Istanbul Province, Turkey (Not_yet_recruiting)

Study contacts

• Principal investigator: Miguel ESCOBAR, MD — The University of Texas Health Science Center, Houston
• Study coordinator: Eric CARBONNELLE (for the only use of healthcare professionals)

Conditions Hemophilia